Herceptin.net - Herceptin for Early Breast Cancer

Adjuvant Herceptin delivers high cure rates for women with HER2-positive early breast cancer

Clinical trial data with Herceptin (trastuzumab) in the treatment of EBC show that it is now possible to change the natural history of HER2-positive breast cancer, with high cure rates an achievable goal.

Herceptin for 1 year is the foundation of care for women with HER2-positive early breast cancer

1-year of adjuvant Herceptin is mandated as the standard of care by international guidelines (NCCN and St Gallen) for the treatment of women with HER2-positive EBC

EU approval and labelling information

Herceptin is approved for the treatment of women with early and metastatic HER2-positive breast cancer and patients with HER2-positive metastatic gastric cancer.

Dosage and administration

Recommendations for dosage and administration of Herceptin.

Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Privacy statement
Legal statement
Contact